|
1
|
Chu H, Wang M and Zhang Z: Bladder cancer
epidemiology and genetic susceptibility. J Biomed Res. 27:170–178.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bellmunt J, Orsola A, Leow JJ, Wiegel T,
De Santis M and Horwich A; ESMO Guidelines Working Group. Bladder
cancer: ESMO Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 25(Suppl 3): iii40–iii48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pang KH and Catto JWF: Bladder cancer.
Surgery. 31:523–529. 2013.
|
|
4
|
Leow JJ, Martin-Doyle W, Rajagopal PS,
Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL,
Choueiri TK, et al: Adjuvant chemotherapy for invasive bladder
cancer: a 2013 updated systematic review and meta-analysis of
randomized trials. Eur Urol. 66:42–54. 2014. View Article : Google Scholar
|
|
5
|
Herr HW, Dotan Z, Donat SM and Bajorin DF:
Defining optimal therapy for muscle invasive bladder cancer. J
Urol. 177:437–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drayton RM and Catto JW: Molecular
mechanisms of cisplatin resistance in bladder cancer. Expert Rev
Anticancer Ther. 12:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sonpavde G and Sternberg CN: Neoadjuvant
chemotherapy for invasive bladder cancer. Curr Urol Rep.
13:136–146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar
|
|
9
|
Anreddy N, Gupta P, Kathawala RJ, Patel A,
Wurpel JN and Chen ZS: Tyrosine kinase inhibitors as reversal
agents for ABC transporter mediated drug resistance. Molecules.
19:13848–13877. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu CP, Hsieh CH and Wu YS: The emergence
of drug transporter-mediated multidrug resistance to cancer
chemotherapy. Mol Pharm. 8:1996–2011. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gillet JP, Efferth T and Remacle J:
Chemotherapy-induced resistance by ATP-binding cassette transporter
genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
|
|
12
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: Evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dean M and Annilo T: Evolution of the
ATP-binding cassette (ABC) transporter superfamily in vertebrates.
Annu Rev Genomics Hum Genet. 6:123–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gilmore TD and Wolenski FS: NF-κB: Where
did it come from and why? Immunol Rev. 246:14–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghosh G, Wang VY, Huang DB and Fusco A:
NF-κB regulation: Lessons from structures. Immunol Rev. 246:36–58.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun SC and Ley SC: New insights into
NF-kappaB regulation and function. Trends Immunol. 29:469–478.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li F, Zhang J, Arfuso F, Chinnathambi A,
Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: NF-κB in cancer
therapy. Arch Toxicol. 89:711–731. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guan Z, Ding C, Du Y, Zhang K, Zhu JN,
Zhang T, He D, Xu S, Wang X and Fan J: HAF drives the switch of
HIF-1α to HIF-2α by activating the NF-κB pathway, leading to
malignant behavior of T24 bladder cancer cells. Int J Oncol.
44:393–402. 2014.
|
|
19
|
Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL,
Chao CH, Yamaguchi H, Yang NK, Ding Q, et al:
Epithelial-mesenchymal transition induced by TNF-α requires
NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res.
72:1290–1300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayakawa M, Miyashita H, Sakamoto I,
Kitagawa M, Tanaka H, Yasuda H, Karin M and Kikugawa K: Evidence
that reactive oxygen species do not mediate NF-kappaB activation.
EMBO J. 22:3356–3366. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takase O, Yoshikawa M, Idei M, Hirahashi
J, Fujita T, Takato T, Isagawa T, Nagae G, Suemori H, Aburatani H,
et al: The role of NF-κB signaling in the maintenance of
pluripotency of human induced pluripotent stem cells. PLoS One.
8:e563992013. View Article : Google Scholar
|
|
22
|
Widera D, Mikenberg I, Elvers M,
Kaltschmidt C and Kaltschmidt B: Tumor necrosis factor alpha
triggers proliferation of adult neural stem cells via IKK/NF-kappaB
signaling. BMC Neurosci. 7:642006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Widera D, Mikenberg I, Kaltschmidt B and
Kaltschmidt C: Potential role of NF-kappaB in adult neural stem
cells: The underrated steersman? Int J Dev Neurosci. 24:91–102.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zahreddine H and Borden KL: Mechanisms and
insights into drug resistance in cancer. Front Pharmacol. 4:282013.
View Article : Google Scholar : PubMed/NCBI
|
